Back to Clinical Trials
Phase 2Recruiting

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

Sponsored by InventisBio Co., Ltd

About this study

A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants with Moderate to Severe Plaque Psoriasis

Where this study is enrolling (19)

Show all 19 locations
Who can participate

Inclusion criteria

  • ✓Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent
  • ✓Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3.
  • ✓Within normal ranges of laboratory assessments

Exclusion criteria

  • ✕Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.